肿瘤原发部位对mCRC转归的影响主要开始于美国 CALGB/SWOG 80405 研究的亚组研究中。80405 研究原来是一项失败的临床试验,推定西妥昔单抗(CET)联合化疗的治疗效果优于贝伐珠单抗(BV)联合化疗。虽然从近 6000 个病例的研究分析得出,两组总...
TAS-102 (35 mg/ m²) was given orally twice daily on days 1 -5 and 15 -19 in a 4-weeks cycle, and BV (5 mg/ kg) was administered by intravenous infusion for 30 min in every 2 weeks. The primary endpoint was PFS, and the secondary endpoints were response rate (RR), disease...
Subsequently, the combination of TAS-102 and bevacizumab (BV) has ... Y Yoshida,T Yamada,H Matsuoka,... - 《Annals of Oncology》 被引量: 0发表: 2019年 Usefulness of TAS-102 as Third-line Chemotherapy for Metastatic Colorectal Cancer BACKGROUND/AIM: The feasibility and oncological outcomes ...
TAS-102 and bevacizumab combination therapy is a cost-effective option for patients who have metastatic colorectal cancer in the Japanese health care system. Peer Review reports Introduction In Japan, approximately 150,000 new patients per year are currently diagnosed as colorectal cancer (CRC), and ...
TAS-102 in metastatic colorectal cancerdoi:10.1016/S1470-2045(17)30927-0Talha Khan BurkiElsevier BVLancet OncologyBurki TK. TAS-102 in metastatic colorectal cancer. Lancet Oncol. 2018;19(1):e18.
更多实用攻略教学,爆笑沙雕集锦,你所不知道的游戏知识,热门游戏视频7*24小时持续更新,尽在哔哩哔哩bilibili 视频播放量 2、弹幕量 0、点赞数 0、投硬币枚数 0、收藏人数 0、转发人数 0, 视频作者 窝趣窝趣窝趣66, 作者简介 ,相关视频:104,太空杀新模式,《国服寒冰射
Background TAS-102 improved overall survival of metastatic colorectal cancer (mCRC) patients with median progression-free survival (PFS) of 2.0 months (RECOURSE trial). Subsequently, the combination of TAS-102 and bevacizumab (BV) has been shown to extend median PFS to 3.7 months (C-TASK FORCE...
更多实用攻略教学,爆笑沙雕集锦,你所不知道的游戏知识,热门游戏视频7*24小时持续更新,尽在哔哩哔哩bilibili 视频播放量 0、弹幕量 0、点赞数 0、投硬币枚数 0、收藏人数 0、转发人数 0, 视频作者 窝趣窝趣窝趣66, 作者简介 ,相关视频:103,9 1,科吹解析D2 - T1的最强